Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Impact of Anosognosia on Clinical and Patient-Reported Assessments of Psychiatric Symptoms in Huntington’s Disease

The Impact of Anosognosia on Clinical and Patient-Reported Assessments of Psychiatric Symptoms in... Background:Psychiatric symptoms are widely prevalent in Huntington’s disease (HD) and exert greater impact on quality of life than motor manifestations. Despite this, psychiatric symptoms are frequently underrecognized and undertreated. Lack of awareness, or anosognosia, has been observed at all stages of HD and may contribute to diminished patient self-reporting of psychiatric symptoms.Objective:We sought to evaluate the impact of anosognosia on performance of commonly used clinical rating scales for psychiatric manifestations of HD.Methods:We recruited 50 HD patients to undergo a formal psychiatrist evaluation, the Problem Behavior Assessment-Short Form (PBA-s), and validated self-report rating scales for depression, anxiety, and anger. Motor impairment, cognitive function, and total functional capacity were assessed as part of clinical exam. Patient awareness of motor, cognitive, emotional, and functional capacities was quantified using the Anosognosia Rating Scale. Convergent validity, discriminant validity, classification accuracy, and anosognosia effect was determined for each psychiatric symptom rating scale.Results:Anosognosia was identified in one-third of patients, and these patients underrated the severity of depression and anxiety when completing self-report instruments. Anosognosia did not clearly influence self-reported anger, but this result may have been confounded by the sub-optimal discriminant validity of anger rating scales.Conclusion:Anosognosia undermines reliability of self-reported depression and anxiety in HD. Self-report rating scales for depression and anxiety may have a role in screening, but results must be corroborated by provider and caregiver input when anosognosia is present. HD clinical trials utilizing patient-reported outcomes as study endpoints should routinely evaluate participants for anosognosia. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Huntington's Disease IOS Press

The Impact of Anosognosia on Clinical and Patient-Reported Assessments of Psychiatric Symptoms in Huntington’s Disease

Download PDF
12 pages

Loading next page...
 
/lp/ios-press/the-impact-of-anosognosia-on-clinical-and-patient-reported-assessments-I46R6a0038

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
IOS Press
Copyright
Copyright © 2020 © 2020 – IOS Press and the authors. All rights reserved
ISSN
1879-6397
eISSN
1879-6400
DOI
10.3233/JHD-200410
Publisher site
See Article on Publisher Site

Abstract

Background:Psychiatric symptoms are widely prevalent in Huntington’s disease (HD) and exert greater impact on quality of life than motor manifestations. Despite this, psychiatric symptoms are frequently underrecognized and undertreated. Lack of awareness, or anosognosia, has been observed at all stages of HD and may contribute to diminished patient self-reporting of psychiatric symptoms.Objective:We sought to evaluate the impact of anosognosia on performance of commonly used clinical rating scales for psychiatric manifestations of HD.Methods:We recruited 50 HD patients to undergo a formal psychiatrist evaluation, the Problem Behavior Assessment-Short Form (PBA-s), and validated self-report rating scales for depression, anxiety, and anger. Motor impairment, cognitive function, and total functional capacity were assessed as part of clinical exam. Patient awareness of motor, cognitive, emotional, and functional capacities was quantified using the Anosognosia Rating Scale. Convergent validity, discriminant validity, classification accuracy, and anosognosia effect was determined for each psychiatric symptom rating scale.Results:Anosognosia was identified in one-third of patients, and these patients underrated the severity of depression and anxiety when completing self-report instruments. Anosognosia did not clearly influence self-reported anger, but this result may have been confounded by the sub-optimal discriminant validity of anger rating scales.Conclusion:Anosognosia undermines reliability of self-reported depression and anxiety in HD. Self-report rating scales for depression and anxiety may have a role in screening, but results must be corroborated by provider and caregiver input when anosognosia is present. HD clinical trials utilizing patient-reported outcomes as study endpoints should routinely evaluate participants for anosognosia.

Journal

Journal of Huntington's Disease – IOS Press

Published: Oct 8, 2020

References

  • Neuropsychiatric aspects of Huntington’s disease
    Paulsen
  • Observing Huntington’s disease: The European Huntington’s disease network’s registry
    Orth
  • Neuropsychiatric symptoms in a European Huntington’s disease cohort (REGISTRY)
    Van Duijn
  • Patient and caregiver quality of life in Huntington’s disease
    Ready
  • Changes in mental state and behaviour in Huntington’s disease
    Eddy
  • Health-related quality of life in Huntington’s disease: Which factors matter most?
    Ho
  • Suicidal ideation in Huntington disease: The role of comorbidity
    Wetzel
  • Suicidal ideation in a European Huntington’s disease population
    Hubers
  • Systematic review of pharmacological treatments for depressive symptoms in Huntington’s disease
    Moulton